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Executive Summary 
Aims and Approach 
This report builds on chapter 2 of the report of the expert panel review, and provides an 
overview of the current available evidence on New Psychoactive Substances (NPS)1.  
Findings 
Identification of NPS  
 Forensic analysis of NPS samples and seizures suggests the rate at which NPS are 
appearing on the European market is increasing. The Early Warning System run by the 
European Monitoring Centre for Drug and Drug Addiction (EMCDDA) detected 81 
novel2 NPS in 2013, an increase from 74 in 2012, 49 in 2011 and 41 in 2010 
(EMCDDA-Europol, 2014). 
 The picture in the UK is slightly different, with greater year-to-year variation. The UK 
reported 11 substances for the first time to the EMCDDA in 2013, a fall from 13 in 2012, 
the same as 2011 and down from the 16 reported in 2010 (Home Office, 2014a). 
 Many of the NPS detected are part of groups of similar substances with similar effects 
(such as cathinones), or dissimilar substances that produce similar effects (such as 
synthetic cannabinoids). This is unlike many traditional illicit drugs, such as cocaine, 
cannabis, ecstasy and heroin, which all have distinct effects. 
 It is likely that most of the substances identified by early warning systems are not in 
widespread or even limited use.  
Prevalence of NPS use 
 The Crime Survey for England and Wales (CSEW) reports that mephedrone use has 
fallen since measurements began in 2010/11. Last year use of mephedrone among 
adults (16- to 59-year-olds) was 1.3 per cent in 2010/11; it then fell to 1.0 per cent in 
2011/12 and to 0.5 per cent in 2012/13, before stabilising in 2013/14 (0.6%) (Home 
Office, 2014b). 
 Mephedrone use tends to be higher than other types of NPS. In the 2011/12 CSEW, 
mephedrone use in the last year among adults (16- to 59-year-olds) was higher (1.0%) 
than any other NPS measured in the survey that year (GBL/GHB, spice and BZP were 
0.1%). However, as mephedrone use has fallen, use is at a similar level to salvia (0.5%) 
(Home Office, 2014b).  
                                               
1 The Home Office’s expert review panel defined New Psychoactive Substances as: ‘Psychoactive drugs, newly available in 
the UK, which are not prohibited by the United Nations Drug Conventions but which may pose a public health threat 
comparable to that posed by substances listed in these conventions.’ 
2 For the purposes of this report, novel NPS are NPS that have not previously been reported. 
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 NPS use is higher in certain subgroups, such as participants in the night-time economy 
(NTE) and men who have sex with men. A decline in mephedrone use between 2010 
and 2013 is reported by the Global Drugs Survey3 of regular clubbers (Mixmag, 2014). 
However, other small-scale surveys of clubbers at gay-friendly nightclubs have shown 
that mephedrone use may have increased from 2010 to 2011 (Measham et al., 2011a; 
Wood et al., 2012a). 
 The CSEW and Global Drug Survey both show that use of mephedrone has declined 
since it was controlled. However, it is not possible to isolate the impact of legislation as 
opposed to other factors. 
 A large proportion of NPS contain mixtures of substances (Home Office, 2014b). This 
limits the validity of data gained from studies that rely on self-reported use of NPS, as 
users cannot know what they are taking.  
Characteristics of NPS users 
 Evidence from surveys show that NPS use is predominantly confined to existing 
traditional illicit drug users. For example, the 2013/14 CSEW found that of those who 
used mephedrone in the last year, 98 per cent had taken another illicit drug in the last 
year. 
 As such, the profile of NPS users is broadly similar to the profile of club drug users; both 
are generally young, male, and active participants in the night-time economy (Home 
Office, 2014b).  
 Some NPS users may not have a preference for specific substances and instead are 
seeking generic stimulant-type drugs (i.e. any white powder) (Measham et al., 2011b). 
The market for NPS  
 Non-controlled NPS are commonly sold from headshops and ‘clearnet’4 retailers. As 
well as other sources, controlled NPS are available from the ‘darkweb’5, but research 
shows that users mainly purchase traditional illicit drugs this source (Barratt et al., 
2013a). 
 While NPS are readily available online, only a minority of NPS users acquire their drugs 
through online sources (European Commission, 2014). Instead, NPS users reported 
purchasing from friends, dealers and headshops. 
 Retailers will often mark their products ‘not for human consumption’ and therefore 
provide no information about the use or harms of NPS  
 Producers may quickly adapt to substance by substance controls by marketing similar 
compounds that are not controlled (Dargan et al., 2011). 
                                               
3 The Global Drug Survey is a self-selecting online survey that was initially aimed at readers of the dance music/clubbing 
magazine Mixmag. Findings relate to those who are regular clubbers (i.e. those that have been clubbing in the past month).  
4 The ‘clearnet’ refers to websites that are openly available on the internet. 
5 The ‘darkweb’ refers to websites that are not openly available on the internet, and can only be accessed with anonymising 
software such as TOR. 
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 Since classification, there is some evidence that the remaining residual market for 
mephedrone has shifted to illicit suppliers, consequently, the price of mephedrone has 
increased, the purity has decreased, and there may have been a shift towards 
purchasing mephedrone from dealers (Davies and Murray, 2013; Winstock, et al., 
2010a). 
 The extent to which NPS are purchased in bulk over the internet for further distribution 
is uncertain. 
 NPS can contain controlled drugs. In 2013/14, of the substances found by the Home 
Office’s Forensic Early Warning System within NPS samples, 3.0 per cent of those from 
the internet, and 4.3 per cent of those from headshops were controlled NPS (Home 
Office, 2014a).  
Motivations for NPS use 
 Similarly to traditional illicit drugs, the main factors that drove mephedrone use were 
market factors such as price and availability, and also the perceived higher quality when 
compared to illicit drugs (Dargan et al., 2010; Carhart-Harris et al., 2011). 
 Findings on the importance of the legal status of NPS are mixed. For the majority of 
users, evidence suggests that legality is not the biggest motivator; increased 
convenience, availability and lower prices that arise from the legality appear more 
important. Legality may be more of a motivator for users who have not previously used 
illicit drugs, and for those subject to mandatory drug testing.  
 For existing drug users, the legal status of NPS does not imply safety (for example 
Corazza et al., 2014). However, there is limited evidence that suggests, for those who 
do not use other drugs, this may be the case (Sheridan and Butler, 2009).  
 NPS may be both displacing (i.e. taking the place of illicit drugs) and also 
supplementing (i.e. being used alongside illicit drugs) existing drugs. For example, a 
study of customers at gay-friendly dance clubs in south London found that 78 per cent 
of those who had used mephedrone within the past month had also used MDMA 
powder in the past month (Moore et al., 2013). 
Health harms 
 In 2013, there were 60 deaths where an NPS was mentioned on the death certificate. 
NPS deaths are relatively low compared to the total of 1,957 deaths from drug misuse 
overall. However, there have been increases in NPS related deaths over recent years 
with a sharp rise from 29 to 52 deaths from 2011 to 2012 (Office for National Statistics, 
2014a). 
 There has been an increase in the number of people entering treatment reporting 
mephedrone use, from 839 in 2010/11 to 1,630 in 2012/13 (Public Health England, 
2013). These people comprise a small amount of the overall treatment population and 
generally have positive treatment outcomes. 
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 Between 2011/12 and 2012/13 there were increases in the number of telephone 
enquiries (49%) and TOXBASE accesses (128%) to the National Poison Information 
Service6 regarding NPS (National Poison Information Service, 2013).  
Social harms 
 Research on the social harms of NPS use is limited. However, it is plausible that the 
social harms of NPS use are equivalent to those of other recreational/ club drugs 
(ACMD, 2009). That is to say, at present, it is likely that NPS use is not significantly 
driving crime, anti-social behaviour and other social harms.  
Conclusion 
 NPS is a new and developing area of study. Many innovative methodologies are being 
used and conventions surrounding how best to research NPS are still being established. 
 There is good evidence on the identification of new NPS, and evidence on the use of 
NPS is also well established, albeit with some limitations. 
 However, there are gaps in the evidence on:  
o the prevalence of use of NPS, and a total measure of NPS use; 
o the use of NPS among subgroups other than NTE participants; 
o the long-term health harms of NPS use; 
o acute health harms of NPS use; 
o the extent to which NPS use drives social harms;  
o the impact and effectiveness of legislation; 
o the motivations for the use of NPS other than mephedrone; 
o the exact factors and mechanisms that affect displacement and supplementation; 
and 
o the extent to which individuals within social groups purchase online and then 
distribute within their social group. 
                                               
6 The National Poisons Information Service provides information and advice to health professionals through telephone 
enquires and also through online access to its TOXBASE service.  
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1. Introduction 
In December 2013 the Home Office appointed an expert panel to look at the UK’s current 
legislative response to New Psychoactive Substances (NPS) and whether it could be 
enhanced beyond the Misuse of Drugs Act 19717. In addition, the panel considered the 
Government’s health and education responses to NPS. 
This report builds on chapter 2 of the report of the expert panel review and provides an 
overview of the current available evidence on NPS. It is published alongside the report of the 
expert panel review and the Government’s response to their report. 
1.1 Approach 
The main sources used for this report are peer-reviewed academic research, official 
statistics, and reports from national and international agencies. To enhance our 
understanding in certain areas, additional statistics have also been produced for this report. 
While this is not a systematic review of the literature, the majority of the publicly available 
evidence in this area has been accessed. This report also covers evidence that has become 
newly available since the expert panel considered the evidence base on NPS. 
The report has given priority to research and data relating to England, although some data 
covers a wider geographical area. In some areas where no UK research exists, appropriate 
international evidence has been drawn upon. 
A large proportion of the research on NPS users has focused on mephedrone; this is not 
surprising, as mephedrone has been unique in achieving relatively high levels of use. 
However, given the increased popularity of mephedrone over other NPS, the findings from 
these studies may not be applicable to users of other NPS. In addition, a great deal of 
research into NPS was conducted before or immediately after the classification of 
mephedrone in April 2010 so the findings may not be applicable to the current NPS situation. 
1.2 Definition 
New Psychoactive Substances is a generic term for the relatively recent phenomenon of 
substances produced to mimic the effects of traditional illicit drugs8. NPS is not a perfect 
term, as some were first synthesised a considerable time ago and are not inherently ‘new’, 
just newly available or newly misused. Other expressions to describe NPS, such as ‘legal 
highs’, are inaccurate and unhelpful as many NPS have been controlled under the Misuse of 
Drugs Act 1971, and therefore NPS can refer to both controlled and non-controlled 
substances. 
                                               
7 See ‘NPS Review: report of the expert panel’ for further information. 
8 Throughout this report, the phrase ‘traditional illicit drugs’ is used to describe established drugs of misuse, 
such as cocaine, ecstasy and cannabis. 
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Notwithstanding these issues, the Home Office’s expert review panel defined New 
Psychoactive Substances as:  
‘Psychoactive drugs, newly available in the UK, which are not prohibited by the United 
Nations Drug Conventions but which may pose a public health threat comparable to 
that posed by substances listed in these conventions.’ 
The emergence of new drugs is not in itself a new phenomenon. However, the speed and 
scale at which substances are now emerging distinguishes the current NPS situation from 
new drugs that have previously emerged. 
This review is limited to the more recently identified substances. Early warning data suggests 
that the NPS phenomenon started to grow around 2008, and substances that were controlled 
after this date are included. Therefore, for the purposes of this report, mephedrone and GBL 
are considered NPS, but ketamine and ecstasy are not. However, this distinction becomes 
blurred when considering NPS that have become established illicit drugs, as these may have 
more in common with other controlled drugs, rather than the currently uncontrolled NPS. 
Further issues with defining NPS are discussed in Box 1.  
Box 1: Additional definitional issues 
Throughout this report there are issues about which substances are defined as an ‘NPS’. 
This is important because the inclusion or exclusion of substances affects estimations of the 
overall scale of the NPS problem. This is not an issue for research that focuses on specific 
substances, but research that attempts to look at NPS as a whole will be affected. 
Additional definitional issues emerge when considering NPS that have achieved widespread 
use and are now controlled substances. For example, ketamine and mephedrone are now 
well-established recreational drugs that are controlled under the Misuse of Drugs Act 1971. 
Due to this, these would not be covered by definitions that solely focus on the legal status of 
a drug at a UK level. Despite this, mephedrone is still widely considered to be an NPS, and 
some authors and agencies also considered ketamine to be an NPS. As controlled 
substances can still be considered an NPS, it is unclear when a substance ceases to be an 
NPS, and instead becomes a traditional illicit drug. 
Similarly, the exact NPS that are subject to control measures varies across different countries 
(EMCDDA, 2014b). The UK has taken a proactive approach to NPS, and many substances 
that controlled in the UK are not controlled in other countries, or at a European or 
international level. Therefore, definitions that focus on legal status at an international level will 
include a great deal of substances that are already controlled in the UK. 
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1.3 Scope 
This report covers the following areas:  
 the identification and prevalence of NPS use; 
 characteristics of NPS users; 
 motivations for NPS use and displacement from other drugs; 
 the NPS market; 
 deaths related to NPS use, poison centre contacts, and treatment data; and 
 the social harms of NPS use. 
This report does not review the evidence on the toxicology or pharmacology of NPS, nor the 
specific harms posed by individual NPS.  
The Home Office’s Advisory Council on the Misuse of Drugs (ACMD) produces in-depth 
reports primarily on the potential health harms of specific NPS. These can be found at: 
https://www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-
drugs/series/acmd-drug-specific-reports--2.  
The European Monitoring Centre for Drug and Drug Addiction (EMCDDA) also carries out 
risk assessments on NPS. These can be accessed at: 
http://www.emcdda.europa.eu/html.cfm/index16776EN.html  
Also, this report does not cover prevention and treatment interventions, the efficacy of 
different legislative approaches, nor the production and upstream supply of NPS, although 
these are discussed in the expert panel report. 
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2. Identification of NPS 
Data from the forensic analysis of NPS samples and seizures suggests the rate at which 
NPS are appearing on the European market is increasing; however, the situation in the UK is 
less clear, with greater year-to-year variation. 
This chapter covers the various early warning systems detecting novel9 NPS at a national, 
European and international level. These systems provide a comprehensive and responsive 
mechanism for the reporting of new substances, but it is possible that as forensic capability to 
detect NPS has improved some of the increases in incidence may be down to improved 
standards of detection. It is also important to note that the purpose of these systems is to 
identify the presence of new substances and as such they are not a measure of the scale of 
availability and use.  
The EMCDDA detects novel NPS through reports to their Early Warning System (EWS). 
Figure 1 shows the increasing rate at which the EWS is detecting NPS (EMCDDA, 2014a). In 
2013, 81 novel NPS were detected, an increase from 74 in 2012, 49 in 2011 and 41 in 2010.  
Of the 81 novel substances identified in 2013, the largest group (29) were synthetic 
cannabinoids. This continues the increase in the number of different synthetic cannabinoids 
identified over the last three years. The number of new cathinones (such as mephedrone) 
identified has reduced since a peak of 14 in 2010, with 7 being identified in 2013.  
There is also evidence of increasing diversification, with an increase of NPS identified that fall 
outside the previously used common classifications10. In response the EMCDDA has 
expanded the number of categories for 2013. 
                                               
9 For the purposes of this report, novel NPS are NPS that have not previously been reported. 
10 The EMCDDA previously used six classifications: Other (chemicals, plants, medicines), Synthetic cannabinoids, 
Cathinones, Piperazines, Tryptamines, and Phenethylamines. This has been expanded to the twelve categories listed in 
figure 1. 
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Figure 1: Number and main groups of NPS notified to the EMCDDA Early Warning 
System, 2005 to 2013  
 
In 2013, the UK reported 11 substances for the first time to the EMCDDA, a fall from 13 in 
2012, the same as 2011 and down from the 16 reported in 2010 (Home Office, 2014a). 
These substances are identified in the UK by a variety of organisations, including the Home 
Office’s Forensic Early Warning System (FEWS), other Forensic Science Providers (FSPs), 
law enforcement casework and other systems. Of the 11 detected, 2 were first identified by 
FEWS. This is lower than previous years (10 between April 2012 and March 2013, and 17 
between January 2011 and March 2012) (Home Office, 2013a)11. 
Globally there is a similar picture to the EWS trends; the United Nations Office on Drugs and 
Crime (2014) reported that by 2013, 348 NPS had been reported by member states, up from 
166 in 2009. In 2012, the number of NPS reported overtook the total number of substances 
under international control (234). The UNODC concluded that: ‘the international drug control 
system is floundering, for the first time, under the speed and creativity of the phenomenon 
known as new psychoactive substances’ (UNODC, 2013a). 
It is highly likely that many substances identified by forensic analysis are not in widespread or 
even limited use. Most substances detected by international warning systems have a limited 
geographic distribution, and are only detected in one or two countries. Around half (42) of the 
NPS reported to the EMCDDA’s EWS in 2013 were only detected in one EU member state, 
and only four substances were detected in five or more EU member states (see Figure 2). 
                                               
11 The overall number reported to the EMCCDA is more stable, albeit with year-to-year variation. It is likely that the number 
of substances identified for the first time by FEWS has fallen as other organisations have detected them first, with many of 
the substances being identified by FEWS at a later date. 
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Similarly, of the 348 substances reported to the UNODC, 101 have only been reported once 
(Levissianos, 2014). 
Figure 2: Number of member states where substances reported to the EMCDDA have 
been detected, EU, 2013 
 
Additionally, it is important to note that many of the NPS detected are part of groups of similar 
substances with similar effects (such as cathinones), or dissimilar substances that produce 
similar effects (such as synthetic cannabinoids). This is unlike many traditional illicit drugs, 
such as cocaine, cannabis, ecstasy and heroin, which all have distinct effects. Similarly, 
despite the large number of substances detected, many of these are already controlled in the 
UK. As of March 201412, 64 per cent (241 out of 377) of the substances listed on the 
European Database on New Drugs were controlled in the UK under the Misuse of Drugs Act 
1971 (Home Office, 2014c). This is highest for cathinones, with 53 out of 56 being controlled, 
and lower for other groups such as opioids (6 out of 11 controlled) and synthetic 
cannabinoids (68 out of 111 controlled).  
                                               
12 New controls have been introduced since this date, which would increase the percentage of substances under control. 
However, new substances have also been detected, which may decrease the percentage of substances under control. 
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3. Prevalence of NPS use  
There are several sources of data on the prevalence of NPS use, from the nationally 
representative Crime Survey for England and Wales (CSEW) to smaller surveys focusing on 
specific subgroups. These sources tend to show that use of NPS in the general population is 
low compared to the use of traditional illicit drugs, but that use of NPS is higher in certain 
subgroups. 
This chapter covers the prevalence of NPS use in both the general population and certain 
subgroups. The subgroups covered are: participants in the night-time economy, clubbers, 
men who have sex with men, school children, young adults, and psychonauts13. Potential 
approaches to improving data on NPS use are discussed at the end of the chapter in Box 2. 
3.1 Use of NPS in the general population 
Overall, reported use of NPS in the general population remains low compared to some 
traditional illicit drugs. Of all the NPS asked about, mephedrone achieved the highest levels 
of use, but use has fallen since peaking in 2010/11.  
3.1.1 Crime Survey for England and Wales (CSEW)  
The CSEW14 is the only nationally representative, random sample survey on drug use in 
England and Wales. It is a general population household survey that covers adults (aged 16 
to 59) in England and Wales. The CSEW provides the best population level data on NPS use 
but there are some general limitations15 and some specific to NPS. It is challenging to keep 
pace with the evolving NPS market and, as only a minority of NPS are likely to be in 
widespread use, limited use may not be picked up in large-scale surveys of this type. 
Furthermore, NPS are typically only added to the CSEW when awareness has been raised 
from other sources; for example, mephedrone was added in the 2010/11 survey, after it had 
already been controlled.  
Questions on selected NPS (GBL/GHB, BZP and spice) were first added into the CSEW in 
2009/1016; these were taken out and replaced with salvia in 2013/14. Mephedrone was 
added in 2010/11 and, due to the relatively high prevalence of use, is now routinely included 
in the survey.  
                                               
13 ‘Psychonauts’ as a term is sometimes used to refer to those who experiment with psychoactive drugs. 
14 Formerly the British Crime Survey (BCS). 
15 An established problem with household surveys such as the CSEW is that marginal groups, for example homeless people 
or people in institutions, are inadvertently excluded from the sample. As drug use in these groups may be higher than in the 
general population, overall drug use may be higher than measured by the CSEW. This is likely to be most apparent for the 
least commonly used drugs such as heroin. Additionally, due to the scale of the survey there is a considerable time lag 
between the survey being run and the results being published. 
16 Questions on GBL/GHB, BZP and spice were added in October 2009, therefore only six months of data are available for 
this year, rather than the usual 12 months. However, as each quarter of the CSEW is nationally representative, these figures 
are still robust. 
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The CSEW shows that reported mephedrone use has fallen since measurements began in 
2010/11 (see Table 1)17. Last year use of mephedrone among adults aged 16 to 59 was 1.3 
per cent in 2010/11; it then fell to 1.0 per cent in 2011/12 and to 0.5 per cent in 2012/13. Use 
then stabilised between 2012/13 and 2013/14.  
Use of other NPS in the CSEW has been relatively low compared with mephedrone, although 
there was a significant increase in reported use of salvia between 2012/13 and 2013/14 
(Home Office, 2014b). 
Table 1: Proportion of 16- to 59-year-olds reporting last year use of NPS, England and 
Wales, 2009/10 to 2013/14 
% 2009/10 2010/11 2011/12 2012/13 2013/14 
Mephedrone N/A 1.3 1.0 0.5 0.6 
GBL/GHB 0.1 0.0 0.1 N/A N/A 
BZP 0.4 0.1 0.1 N/A N/A 
Spice 0.3 0.2 0.1 N/A N/A 
Salvia N/A N/A N/A 0.3 0.5 
Unweighted Base 12,992 27,451 26,831 21,621 21,982 
 
Similarly to most other drug types, use of NPS is higher among young adults. However, the 
survey shows a general downward trend in the use of NPS (see Table 2). As for all adults 
mephedrone has historically been the most used NPS, with use in the last year reaching a 
peak of 4.4 per cent in 2010/11 compared with 1.9 per cent in 2013/14. As with adults, use of 
the other NPS measured in the 2011/12 survey was low, although reported use of salvia in 
2013/14 was at a similar level to mephedrone.  
Table 2: Proportion of 16- to 24-year-olds reporting last year use of NPS, England and 
Wales, 2009/10 to 2013/14 
% 2009/10 2010/11 2011/12 2012/13 2013/14 
Mephedrone N/A 4.4 3.3 1.6 1.9 
GBL/GHB 0.5 0.1 0.2 N/A N/A 
BZP 1.3 0.2 0.1 N/A N/A 
Spice 1.2 0.4 0.3 N/A N/A 
Salvia N/A N/A N/A 1.1 1.8 
Unweighted Base 1,705 3,667 3,559 2,728 2,726 
 
                                               
17 As population estimates from the 2011 Census are now available, previous estimates of drug use have been re-weighted 
using these new estimates. This means that some of figures in the 2013/14 Drug Misuse publication are different from the 
previous published trends. For example, last year use of mephedrone among adults (16 to 59) was previously estimated to 
be 1.4 per cent in 2010/11; this has now changed to 1.3 per cent following the re-weighting. 
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The CSEW shows that use of mephedrone has declined following control in 2010. The 
reduction and control happened over the same time period. However, it is plausible that other 
factors such as increasing reports of the health harms of mephedrone use, and the 
increasing quality of other comparable illicit drugs also contributed to the fall (Wood and 
Dargan, 2012c/e; Daly, 2011). As it is not possible to establish a counterfactual, it is not 
possible to isolate the specific impact of these different factors. 
3.2 Use of NPS in subgroups 
There are relatively high levels of NPS use in specific subgroups, such as clubbers and men 
who have sex with men, compared to the general population. There is evidence from the 
CSEW to support this, as well as a range of other research, which focuses on particular 
subgroups. 
Other research tends to show higher rates of use than the CSEW, but due to the sometimes 
small-scale and self-selecting nature of the other research in this area, it cannot be used to 
generalise or identify nationally representative trends. Nevertheless, when used alongside 
other sources, it helps build a more in-depth picture to understand the use of NPS. 
3.2.1 Participants in the night-time economy (NTE) 
There is strong evidence of an association between higher levels of use of both traditional 
illicit drugs and NPS among those who regularly visit pubs and clubs. For example, the 
CSEW found that those who had visited a nightclub four or more times in the last month were 
about five times more likely to have used any illicit drug in the last year, compared with those 
who had not visited a nightclub (32.5% and 6.5% respectively) (Home Office, 2014a). 
Of the NPS measured in the CSEW, breakdowns by night-time economy participation are 
only available for mephedrone. This shows that last year use of mephedrone was highest 
among adults who had visited a nightclub on four or more occasions in the last month (5.8%), 
compared with those who had been to a nightclub less frequently in the past month (one to 
three visits: 2.1%; no visits: 0.3%). A similar pattern is also visible in pub/wine bar visits (see 
section 4.1 for further demographic breakdowns). This pattern is also seen in traditional illicit 
drugs such as ecstasy and ketamine. 
Other surveys such as the Global Drug Survey, south London nightclub surveys, and 
Lancashire night-time economy surveys also show high levels of use.  
Global Drug Survey 
The Global Drug Survey18 (GDS) is a self-selecting online survey that was initially aimed at 
readers of the dance music/clubbing magazine Mixmag. Its scope has now been widened to 
include other media partners such as the Guardian and Gay Times. In total, 3,591 regular 
clubbers19 in the UK responded to the GDS in 2013/14. 
Although the methodological limitations, summarised below, mean it is not possible to directly 
compare year-on-year findings, results from the 2013/14 GDS suggest that mephedrone use 
                                               
18 Formerly the Mixmag Drug Survey 
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among regular clubbers19 is in decline, but that it is still more prevalent than other NPS asked 
about. Mephedrone use peaked in 2010/11 with 51.0 per cent of regular clubbers who 
responded to the survey reporting taking mephedrone in the last year; since then it appears 
to have substantially declined, to 12.5 per cent in 2013/14. Table 3 shows the relatively 
limited popularity of other NPS measured in the 2011/12 survey when compared to 
mephedrone (Mixmag, 2012).  
Table 3: Proportion of regular clubbers reporting last year use of NPS, GDS, 2011/12 
Type of NPS % 
Mephedrone 30 
2C-B 12 
Methoxetamine 6 
2C-I 6 
Synthetic Cannabis 5 
Benzo Fury 3 
MDAI 3 
Methylone 2 
 
While the GDS provides insight into NPS use, it does have limitations. The self-selecting 
sample means the results cannot be generalised to the wider population as the sample may 
be biased towards those who have drug use to report. Additionally, the sample size has been 
increasing each year, which makes year-to-year comparisons problematic20. 
Surveys in the night-time economy 
Surveys in nightclubs have revealed high levels of NPS use and different trends when 
compared to general population surveys. An in-situ survey of ‘gay-friendly’ dance clubs in 
south London in 2010 had 308 responses and found that 27 per cent of participants had 
used, or were planning to use mephedrone that night (Measham et al., 2011a). The same 
study reported that 41 per cent of respondents reported using mephedrone in the past month 
and 52 per cent reported mephedrone use in the past year. Prevalence of other NPS was 
lower: last month use of NRG-121 was 11 per cent and MDAI was four per cent. 
A follow-up study (Wood et al., 2012a) using the same method in the same gay-friendly 
dance clubs in south London gathered 315 responses. It found that: 
 41 per cent of participants had used, or were planning to use mephedrone that night, an 
increase from the 27 per cent in the original study; 
                                               
19 The Global Drug Survey defines regular clubbers as respondents who have been clubbing in the last month.  
20 While the survey tries to control this by reporting ‘regular clubbers’, it is possible this control could have been diluted, from 
dance/rave clubbing where drug use is relatively higher to more mainstream clubbing where drug use is relatively lower. 
21 NRG-1 is a brand name for naphyrone and was marketed as a replacement for mephedrone at the time the survey was 
conducted. However, forensic analysis of test purchases has shown that most NPS sold as NRG-1 did not contain 
naphyrone (Brandt et al., 2010).  
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 a fifth (20.4%) of participants stated that mephedrone was their favourite drug; 
 24 per cent of participants reported use, or were going to use GHB/GBL that night; and 
 two-thirds (65.8%) of participants had reported that they had previously used a ‘legal 
high’ (Wood et al., 2012b).  
However, ‘last month’ and ‘today’ figures were considerably smaller (see Table 4). The majority 
of the sample had tried NPS and mephedrone was by far the most prevalent. Among customers 
in gay-friendly dance clubs in south London, mephedrone use is considerably higher than any 
other NPS. Additionally, use of mephedrone has increased since it was controlled.  
Table 4: NPS use in ‘gay-friendly’ south London nightclubs, Wood et al. (2012b)  
% Life-time use Last month Today/Tonight 
Any NPS 65.8 N/A  N/A 
Mephedrone 63.8 53.2 41.0 
BZP 9.3 1.6 0.6 
MDAI 7.7 1.3 0.0 
Synthetic Cocaine 9.9 3.5 0.0 
Spice/K2 9.0 2.2 0.6 
Methoxetamine 6.4 1.9 1.6 
Pipradols 1.6 1.0 0.6 
 
These studies, conducted pre- and post-legislation, concluded that ‘the control of 
mephedrone in the UK has not significantly affected its availability, use or appeal to club-
goers in the London night-time economy’ (Measham et al., 2011a; Wood et al., 2012a). Other 
studies have also shown mixed findings with some mephedrone users continuing and others 
desisting (Winstock et al., 2010a; Van Hout and Brennan, 2012; Carhart-Harris et al., 2011). 
Another in-situ survey, of the night-time economy in Lancashire, found high levels of 
mephedrone and ‘Bubble’ use22, with 16 per cent of respondents reporting ‘Bubble’ use in the 
last year and 11 per cent reporting mephedrone use (Measham, et al., 2011c). This was at a 
similar level to some traditional illicit drugs such as speed (11%) and ecstasy (pills 18%, 
powder 14%). Last year use of the other NPS asked about in the survey was low (MDAI and 
NRG-1 were 1%, Ivory wave was 0% (Measham et al., 2011c)). A follow-up survey in 2012 
found lower levels of mephedrone (7%) and bubble (11%) use in the last year. The survey 
also asked about the use of ‘other legal highs’, and found that reported use in the last year 
was eight per cent, a similar level to mephedrone but lower than ecstasy (pills 16%, crystal 
18%) and cocaine (24%) (Measham et al., 2012).  
                                               
22 ‘Bubble’ is a slang term, commonly used in the North West, to describe any NPS with stimulant effects. 
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3.2.2 Men who have sex with men 
There is evidence that there are high levels of traditional illicit drug and NPS use among men 
who have sex with men. Additionally, there is evidence that within certain niche subgroups of 
men who have sex with men, traditional illicit drugs and NPS are being used to facilitate risky 
sexual practices.  
By combining three years of CSEW data, it is possible to analyse drug use by sexual 
orientation. Although the CSEW does not include breakdowns of NPS use by sexual 
orientation, there are figures for use of any illicit drugs in the last year. This shows that gay or 
bisexual men were the group most likely to have taken any illicit drug in the last year (33.0% 
reported taking drugs in the last year), with higher levels of illicit drug use than gay or 
bisexual women (22.9%) and heterosexual men (11.1%) (Home Office, 2014b).  
Other research with men who have sex with men also supports this finding (Hunter et al., 
2014). Additionally, as detailed in the section above, use of NPS in ‘gay-friendly’ dance clubs 
is high. 
As well as a general high level of drug use, there are reports that within certain niche 
subgroups of gay men, certain drugs (including NPS) are being used in a highly sexualised 
context to facilitate or enhance sex. This often involves group sex or a high number of 
partners (Bourne et al., 2014). This phenomenon has been termed ‘chem sex’. Typically the 
drugs used are crystal methamphetamine, mephedrone and GHB/GBL, with crystal 
methamphetamine and mephedrone being injected, and GHB/GBL being taken orally (Kirby 
and Thornber-Dunwell, 2013). ‘Chem sex’ is not an NPS-specific phenomenon, as traditional 
illicit drugs are used alongside NPS. However, as it may involve high-risk behaviours such as 
intravenous drug use and unprotected sex, which can lead to the transmission of HIV and 
other STIs, this is an area of ongoing concern.  
There is a limited amount of research on ‘chem sex’ and it is not possible to quantify the 
overall extent of this phenomenon. Research suggests that it is likely that ‘chem sex’ is 
confined to niche elements of the men who have sex with men scene, largely within London 
and other major metropolitan areas.  
3.2.3 School-aged children 
National Statistics on drug use among 11- to 15-year-olds come from The School Survey of 
Smoking, Drinking and Drug Use. Mephedrone was the first, and currently only, NPS to be 
included in the questionnaire. Two years of data on mephedrone use are available.  
In 2012, 0.7 per cent of pupils reported that they had taken mephedrone in the last year, a 
similar level to use in 2013 (0.4%).23 For comparison, in 2013, 7.0 per cent of pupils reported 
taking cannabis in the last year, and 3.6 per cent of pupils reported taking volatile substances 
(glues, gases, aerosols and solvents) (Fuller and Hawkins, 2014; Fuller, 2013).  
                                               
23 The difference between these figures is not statistically significant.  
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3.2.4 Young adults 
Other surveys of NPS use among young people support the findings from the CSEW. They 
show that, similarly to most other drug types, use of NPS is higher among young people 
relative to the general population.  
A survey of 1,006 Scottish school, college and university students in 2010, prior to the 
classification of mephedrone, found that 20.3 per cent of the sample reported having ever 
used mephedrone (Dargan, et al., 2010). Of those that had used mephedrone, 23.4 per cent 
had only used it on one occasion.  
A European Commission (2014) Eurobarometer poll of over 13,000 young people aged 15 to 
24 years old in EU member states found that eight per cent of respondents reported using 
NPS. The UK was higher than the EU average with 10 per cent reporting use. Caution is 
advised when interpreting the Eurobarometer surveys due to the several reasons:  while the 
overall EU sample is large; the sample for each member state is a relatively low 500, the 
questions used have changed between the 2011 and 2014 surveys making it harder to 
compare between years, and the Eurobarometer survey tends to overestimate usage when 
compared to more robust surveys such as the CSEW. Additionally, as previously mentioned 
in Box 1, the control status of NPS differ between countries, therefore the substances that 
respondents thought were NPS may also have differed between countries.  
3.2.5 Psychonauts 
‘Psychonauts’, is an established term used to refer to those who experiment with 
psychoactive drugs; they often take detailed notes, partake in online discussions and have 
detailed technical knowledge (Davey et al., 2012). Despite the smaller user base when 
compared to recreational users, the potential for serious health harms is high, due to the 
tendency for early experimentation with novel NPS, although as this group often shares 
information on harm minimisation, this may reduce risks (Schifano et al., 2005). Specific 
demographic information about this group is not available, but it seems that the defining 
characteristics of this group are not demographic characteristics, but rather a shared set of 
values and beliefs. However, boundaries between this group and other more recreational 
users remain unclear and there is a clear lack of research in this area.  
 
Box 2: Promising approaches to improving data on NPS use 
Better questionnaire design 
As discussed throughout this chapter, there are a number of limitations in the current 
approaches to measuring NPS prevalence. Whilst the CSEW provides high-quality data on 
the use of specific NPS, it only covers a small range of substances. Other surveys cover a 
wider range of substances but tend to be small-scale and may lack in scope or 
methodological robustness. Some of these surveys are also self-selecting, and the results 
are likely to be biased towards those who have something to report.  
The limitations mean it is difficult to produce robust population measures of the total level of 
NPS use. In response a new group of questions on NPS are being trialled in the CSEW and 
 18 | New Psychoactive Substances in England 
the School Survey for 2014/15 with the aim of improving measurement at population level. 
The new questions build on those developed by the EMCDDA and findings will be available 
in summer 2015. 
Waste water analysis 
A recurring issue in NPS is the difference between how NPS are labelled, marketed and sold 
and the actual psychoactive substances they contain. As detailed in the section ‘NPS 
products’, NPS samples often contain more than one substance (Home Office, 2014b). This 
has implications for the accurate measurement of NPS, particularly for the self- reporting of 
use. Users are, to some extent, likely to be unaware of all substances they are taking which 
may result in the prevalence of some individual NPS and poly-substances being higher than 
the self-reported figures would suggest. 
Emerging techniques around waste water analysis and urine analysis may help to overcome 
issues of self reporting (EMCDDA, 2014c; Chen et al., 2013; Archer et al., 2012; Archer et 
al., 2013). This technique can provide accurate, location-specific and timely information on 
the actual substances being used. As drug metabolites are detected, actual consumption of 
NPS can be determined. However, this technique cannot provide information on individual 
consumption patterns and should therefore be viewed as a complementary method to self-
report survey data, rather than a replacement. 
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4. Characteristics of NPS users 
NPS use is mainly confined to existing drug users. Therefore the demographic profile of NPS 
users is broadly similar to that of an illicit drug user.  
This chapter covers the characteristics of NPS users, including: demographics, the extent to 
which NPS users take other traditional illicit drugs, the emergence of generic stimulant drugs, 
and the injection of NPS.  
4.1 Demographics 
The CSEW reports drug use by a whole range of social and demographic factors (Home 
Office, 2014b). Figure 3 shows the distribution of mephedrone use by age, sex and 
interaction with the night-time economy. 
 Men were twice as likely as women to report last year use of mephedrone (0.9% and 
0.4% respectively). 
 The level of mephedrone use was highest among single adults (1.5%) compared with all 
other marital statuses.  
 Adults living in urban areas were more likely to report that they had used mephedrone in 
the last year compared with adults living in rural areas (0.7% and 0.4% respectively).  
These trends are similar to other traditional illicit drugs, such as cocaine and ecstasy, albeit 
at a lower overall level of use. 
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Figure 3: Proportion of adults aged 16 to 59 reporting last year use of mephedrone, by age 
group, sex and interaction with the night-time economy, England and Wales, 2013/14 
 
Other sources of evidence also show similar demographic profiles to the CSEW, with 
research suggesting that the profile of an NPS user is broadly similar to the profile of other 
illicit drug users and, in particular, to that of a club drug user24. That is to say, both NPS and 
club drug users are generally young males and socially functional (National Treatment 
Agency, 2012).  
The 2009 Global Drug Survey reports that 69.3 per cent of mephedrone users were male 
with an average age of 23.8 years25 (Winstock et al., 2010b). An online survey of 
mephedrone users also showed similar results (Carhart-Harris et al., 2011).  
There is a similar picture for spice: the 2012/13 Global Drug Survey reports that 70.7 per cent 
of spice users are male, with a median age of 26 and almost all (91.5%) identified as White 
(Winstock and Barratt, 2013). Similarly, an online survey of 168 spice users found that 83 per 
cent were male and 90 per cent were White (Vandrey et al., 2012). Additionally, 47 per cent 
were in full-time employment and 28 per cent were students.  
                                               
24 Public Health England (PHE) defines a club drug as a ‘substance typically used by young people in bars and nightclubs, at 
concerts and parties’. 
25 These findings should be considered in the context of the self-selecting nature of the 2009 survey sample, which was itself 
mainly male (65.3%) with a mean age of 25.  
0.0
1.0
2.0
3.0
4.0
5.0
6.0
1
6
–1
9
2
0
–2
4
2
5
–2
9
3
0
–3
4
3
5
–4
4
4
5
–5
4
5
5
–5
9
M
e
n
W
o
m
en
N
o
n
e
1
 t
o
 3
 v
is
it
s
4
 t
o
 8
 v
is
it
s
9
 o
r 
m
o
re
 v
is
it
s
N
o
n
e
1
 t
o
 3
 v
is
it
s
4
 o
r 
m
o
re
 v
is
it
s
Age Gender Number of evening visits
to pub/wine bar in past
month
Number of visits to
nightclub in past
month
P
e
rc
e
n
ta
ge
 New Psychoactive Substances in England | 21 
4.2 Are users of NPS new or existing users of drugs? 
A concern surrounding non-controlled NPS is that they could be attracting a new and naive 
group of drug users. It is supposed that their legal status, veneer of safety and ease of 
availability might attract users that would not engage in illicit-drug-taking activity. The 
available research evidence suggests that these naive users probably comprise a small 
proportion of overall NPS users and that the majority of NPS use is among existing drug 
users.  
The 2013/14 CSEW showed that, of those who had used mephedrone in the last year, 98 per 
cent had taken any other illicit drug in the last year. Within this:  
 80 per cent had taken cannabis in the last year; 
 73 per cent had taken cocaine in the last year; and 
 62 per cent had taken ecstasy in the last year. 
The 2013/14 CSEW also found that, for salvia, an uncontrolled NPS, the majority of users 
(83%) had used another illicit drug in the last year. However, salvia users were less likely to 
have taken cocaine and ecstasy compared to mephedrone users. Of those who used salvia 
in the last year: 
 73 per cent had taken cannabis in the last year; 
 37 per cent had taken ecstasy in the last year; and 
 33 per cent had taken cocaine in the last year. 
Additional research with NPS users supports this finding (Winstock et al., 2013; Sheridan and 
Butler, 2009; Hu et al., 2011; Newcombe, 2009; Barratt et al., 2012; Vandrey et al., 2012; 
Wilkins et al., 2006). The exact figure varies between studies, but research suggests that 
between 83 per cent and 99 per cent of NPS users are also users of other traditional illicit 
drugs.  
There appears to be specific relationships between traditional illicit drugs and the NPS that 
are designed to imitate them. One example is cannabis and synthetic cannabinoids. Analysis 
of the 2,513 spice users who responded to the Global Drug Survey found that 95.0 per cent 
of spice users had also used cannabis in the last year (Winstock et al., 2013). This rises to 
99.3 per cent for lifetime use of cannabis. Interestingly, 93 per cent of respondents preferred 
cannabis to spice. A similar analysis of 582 NBOMe users found that 43.1 per cent had 
lifetime use of magic mushrooms, and 39.4 per cent had lifetime use of LSD (Lawn et al., 
2014). 
Most of the available research has focused on NPS users who have also used other drugs. 
The lack of evidence on naive drug users could be because existing and experienced drug 
users are more numerous than naive users and therefore easier to access for research. This 
is likely, as the balance of the evidence shows that NPS use is largely confined to existing 
drug users. However there is an evidence gap surrounding the small proportion of NPS users 
who do not use other illicit drugs.  
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4.3 The emergence of generic stimulant drugs 
There is emerging evidence to suggest that some NPS users are not expressing preferences 
for specific substances, and instead they are seeking generic stimulant type drugs (i.e. any 
white powder). 
Measham et al. (2011b) describe the emergence of ‘Bubble’ as a generic term for stimulant 
drugs. Within the Lancashire night-time economy, it appears that ‘Bubble’ was initially a slang 
term for mephedrone, but it has now evolved into a term referring to any synthetic legal high 
or white powder with stimulant effect. Of the sample of 207, 18 per cent reported having ever 
used Bubble and 16 per cent reported last year use of Bubble. This is higher than the figures 
for mephedrone from the same sample, at 13 per cent lifetime use and 11 per cent last year.  
Further evidence of this phenomenon comes from the 2013/14 Global Drug Survey. This 
found that 17.5 per cent of regular clubbers had taken a mystery powder in the last year 
(Mixmag, 2014). Of these, 12.9 per cent of respondents thought the powder was 
mephedrone, five per cent thought it was a ‘legal high’ and 5.9 per cent thought it was an 
‘research chemical’ (Mixmag, 2014). Eighty per cent of those who took a mystery powder 
were intoxicated at the time (Mixmag, 2014). This is a similar level to the 2012/13 Global 
Drug Survey, where 20 per cent of regular clubbers reported taking a mystery powder in the 
last year.  
4.4 Injection of NPS 
There are reports from drug treatment workers that a small amount of users are injecting 
mephedrone (Daly, 2012). Overall data on this behaviour is scarce, but it appears that former 
and existing heroin and crack cocaine users are those most likely to inject mephedrone. For 
example, a descriptive study of 11 mephedrone injectors in Ireland found that all participants 
had extensive histories of previous intravenous and poly drug use (Van Hout and Bingham, 
2012). These users seem to inject mephedrone due to a scarcity of their preferred drug, 
therefore this behaviour may be more common in non-urban areas where drug supplies are 
intermittent. Additionally, comments from recreational mephedrone users indicate an 
awareness of the inadvisability of mephedrone injection (Newcombe, 2009; Ryall and Butler, 
2011). Daly (2012) concludes that: 
‘the consensus among drug workers is that, even in the context of heroin and crack use, 
it [mephedrone injection] is a desperate act committed by people with low self-esteem 
living moribund, dead-end existences, away from the country’s major urban centres’. 
As discussed previously, the intravenous use of NPS may also be higher in niche parts of the 
gay scene.  
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5. The market for NPS 
NPS are available from a range of different sources: headshops, other non-specialist 
retailers, the ‘clearnet’, and the ‘darkweb’. Despite ready availability on the clearnet, evidence 
suggests that the most frequent source for NPS users is from their friends, dealers and 
headshops. However, less is known about the social supply of NPS, and these friends may 
be purchasing in bulk from the internet. Analysis of NPS products shows that many contain 
mixtures of several different substances, and some contain controlled drugs.  
This chapter covers the range of different sources for NPS (headshops, other non-specialist 
retailers, the ‘clearnet’, and the ‘darkweb’), the purchasing behaviour of users, the content of 
NPS products, the development of novel NPS, and the illicit supply of NPS.  
5.1 Headshops and other non-specialist retailers 
Non-controlled NPS are often sold from high street outlets called ‘headshops’. The Home 
Office’s expert review panel report defines a headshop as: 
‘Commercial retail outlet specialising in the sale or supply of NPS together with 
equipment, paraphernalia or literature related to the growing, production or consumption 
of cannabis and other drugs. These outlets may also have online businesses, but those 
businesses solely based online would not fit within this definition.’ 
Headshops are not a new type of business, and some headshops have been established for 
many years, selling cannabis paraphernalia and counterculture products. However, with the 
rise in NPS, there have been concerns that the number of headshops may be increasing, 
driven by the opportunities and profit provided by non-controlled NPS, and some may now be 
focusing on the sale of NPS over other products. Headshops are unlikely to be a 
homogenous set of retailers, and there are reports of varying standards of retailing, with 
some headshops aiming to be responsible and only selling to over-18s, and other less 
scrupulous shops selling to children (Daly, 2013; DrugScope, 2014). 
Despite the concern, there is very little robust evidence on the number of headshops in the 
UK, nor on how many of them are selling NPS. The Angelus Foundation26 has estimated that 
there are over 250 headshops in the UK (PRNewswire, 2013). This estimate was produced 
by trawling internet sites and liaisons with Trading Standards officers. The Angelus 
Foundation acknowledges that this estimate may be inaccurate, but given the lack of any 
more reliable estimates, it provides the only indication of the number of headshops in the UK.  
There are also reports that NPS are being sold in non-specialist retailers, such as corner 
shops, petrol stations and takeaways (Daly, 2013; DrugScope, 2014). There is no evidence on 
the overall number of non-specialist retailers selling NPS, but this is an area of concern, as it has 
the potential to introduce NPS to casual users who may not actively seek them out in headshops.  
                                               
26 The Angelus Foundation’s aim is to ‘educate, encourage and assist individuals to be more knowledgeable about the risks 
to their health and wellbeing of using ‘legal highs’ and other new psychoactive substances’ (Angelus Foundation, 2014). 
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5.2 Internet 
An important aspect of the debate around NPS has been the use of the internet in the sale of 
these substances. The evidence in this area suggests that non-controlled NPS are readily 
available on the clearnet, and some controlled NPS are available on the darkweb. Despite 
this, internet purchasing is not as widespread as is commonly suggested, and only a small 
minority of NPS users purchase online.  
5.2.1 Clearnet 
The ‘clearnet’ refers to websites that are openly available on the internet. It is likely that NPS 
retailers on the ‘clearnet’ in the UK will be selling non-controlled NPS, as these websites are 
freely accessible and any illegal items could be quickly identified by law enforcement 
agencies. Those outside the UK may sell NPS that are not controlled in their host jurisdiction, 
but which are controlled in the UK.  
The best available data on the number of NPS internet retailers comes from the EMCDDA 
Snapshots (2014a). These multi-lingual snapshots aim to identify the online availability of 
NPS to users within the EU. The January 2013 snapshot identified 651 online shops selling 
NPS and shipping to at least one EU member state. This is a small decrease from the 693 
identified in the January 2012 snapshot, but was more than twice the number of shops 
identified in January 2011 (314 shops) and a more than a three-fold increase from January 
2010 (170 shops).  
Breakdowns from the January 2014 snapshot are not published, but the substances most 
frequently identified for sale in the January 2012 snapshot were kratom (179) and salvia 
(134), followed by hallucinogenic mushrooms (95), methoxetamine (68), and MDAI (65). The 
other substances in the top ten were 6-APB (54), MDPV (44), 4-MEC (43), methiopropamine 
(39) and 5-IAI (38)(EMCDDA, 2012c). The EMCDDA has made slight changes over time to 
the snapshot method, but despite this these results remain a valid indicator of the growth of 
online shops selling NPS. However, caution is advised when interpreting these figures, as the 
snapshots only show the reported availability of NPS, not the extent to which users are 
actually purchasing NPS online.  
The EMCDDA 2011 snapshot reports that, out of the 631 online shops identified selling to the 
EU, 121 of these were likely based in the UK. These findings are supported by Schmidt et al. 
(2011) who identified 115 UK-based websites selling a total of 1,308 NPS products. 
 The most frequently available products were salvia, kratom, hawaiian baby woodrose 
seeds, fly agaric and a synthetic cannabinoid blend. 
 The average product price was £9.69 but there was significant variation with a minimum 
of £1.75 and a maximum of £54.99. 
 Products were available in a variety of formulations, 46.6 per cent were pills or tablets, 
29.7 per cent were smoking blends, 18.1 per cent were plant material or extract with the 
remainder being powders, liquids, orodispersable strips/gum. 
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 The majority (58.8%) of these were designed to be swallowed, 36.1 per cent smoked 
and 3.8 per cent snorted; 41.7 per cent of products were stimulants, 32.3 per cent were 
sedatives, 12.9 per cent were hallucinogens. 8.1 per cent were mixed and 3.8 per cent 
were aphrodisiacs. 
 40.1 per cent of products did not list ingredients.  
5.2.2 Darkweb 
NPS may also be supplied on the ‘darkweb’. The ‘darkweb’ refers to websites that are not 
openly available on the internet, and can only be accessed with anonymising software such 
as Tor27. As these websites are hidden, and the identity of the seller and buyer are not 
disclosed, the ‘darkweb’ provides a platform for the trade in illicit drugs, including controlled 
NPS. The ‘Silk Road’ is the most well-known example of a ‘darkweb’ drug market, and was 
the initial market leader, but since the ‘Silk Road’ was shutdown by the FBI in October 2013, 
the ‘darkweb’ drug market has become more fragmented, with a wider range of retailers, and 
no clear market leader (Buskirk et al., 2014; Christin, 2012).  
Evidence currently suggests that ‘darkweb’ sites play a small role in the supply of NPS to 
users, with the most popular listing being for illicit drugs such as MDMA and cannabis (Barratt 
et al., 2013a). This is understandable, as there would be little advantage for users to purchase 
non-controlled NPS on the ‘darkweb’ when they are freely available on the ‘clearnet’. The 
anonymity would be a benefit for users purchasing controlled NPS; however, when controlled 
NPS are offered for sale alongside high-quality traditional illicit drugs, it appears that users 
express a preference towards traditional illicit drugs. However, there is emerging evidence that 
these sites may play a greater role in the wholesale supply of NPS (Caudevilla, 2014). 
5.3 The open sale of NPS 
Control of NPS appears to be effective at preventing the open sale of NPS. The ACMD 
(2012b) reported that the methoxetamine ban ‘had a real and immediate impact in tackling 
internet sales’. However, they also stated that it is ‘possible that methoxetamine remains 
available online but sold under other descriptions’. 
There is some evidence that retailers continued to sell NPS after they have been controlled, 
but this may be inadvertent, due to a lack of awareness of what substances were in their 
products. Test purchases from online ‘legal high’ shops by Ramsey et al. (2010) found that 
five out of six products purchased after the April 2010 amendments to the Misuse of Drugs 
Act (1971) contained Class B drugs, despite four being openly advertised as containing legal 
substances only. Given the proximity of these purchases to the April 2010 amendments it is 
possible that suppliers were clearing out products they had purchased prior to classification. 
Similar findings emerged from Dargan et al. (2011), with 85 per cent of spice samples 
purchased after legislation containing a controlled synthetic cannabinoid.  
                                               
27 Tor is a piece of anonymising software that allows users to access hidden websites. 
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To some extent, the market may now have stabilised, as previously mentioned, data from 
FEWS shows that there are now fewer controlled NPS being found in samples from 
headshops and internet retailers. 
5.4 Purchasing behaviours  
Despite NPS being readily available online, and the widely held perception that they are 
purchased online, it appears that most NPS users do not source NPS in this manner.  
The European Commission Eurobarometer (2014) survey of over 13,000 young people in EU 
member states found that three per cent of users purchased NPS over the internet; for the 
UK the figure was slightly higher at six per cent. For the UK, the most popular (58%) route 
was from a friend, followed by drug dealers (39%) and specialist shops (18%). Their findings 
are similar to the 2011 Eurobarometer, which reported that 7.2 per cent of UK NPS users 
purchased online.  
These findings are supported by a survey of over 1,000 school, college and university 
students in Scotland prior to the classification of mephedrone which found that 10.7 per cent 
of users sourced their mephedrone online (Dargan, 2010). The most common (48.8%) 
source of mephedrone was dealers. However, they did observe a link between age and 
increasing preference for online acquisition. Around one in twelve (8.3%) 13- to 15-year-olds 
sourced mephedrone online compared to one in three (30.8%) of those aged over 24. This 
suggests that younger users may lack the necessary financial tools (debit/credit card) and a 
safe delivery address that online purchasing requires. Although not specifically NPS based, 
higher levels of online purchasing were also found in the 2013/14 GDS, with 22.1 per cent of 
UK respondents reporting having ever bought drugs online.  
Low levels of online purchasing have also been found in international research (Matthews 
and Bruno, 2010; Khey, 2008). However, it is worth noting that these figures are higher than 
the one per cent of regular illicit drug users who purchased drugs over the internet (Home 
Office, 2014b). 
These findings suggest that purchasing NPS from the internet is relatively uncommon, but it 
is possible that the internet could play a greater role in social supply, with one friend or dealer 
within a social group purchasing NPS online to resell to others within the group. There are 
reports of this taking place, and of users switching from headshops to online retailers to save 
money (DrugScope, 2014). However, the overall extent to which this is happening remains 
unknown.  
5.5 NPS products 
Uncontrolled NPS are often sold as either branded products such as ‘Benzo Fury’ and 
‘Annihilation’, or specific ‘research chemicals’. However, in many cases there is evidence of 
inconsistency in the content of NPS, with many containing mixtures of different substances 
or, in a minority of cases, controlled drugs. 
Data from the Home Office’s FEWS provides evidence of the scale of this problem. Of the 
samples analysed by FEWS, around nine out of ten were mixtures of either two (61%) or 
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three (30%) different active components. One per cent of samples were identified as 
containing up to six different active components. 
Findings from FEWS also show that some NPS samples contain controlled drugs. In total, 
19.2 per cent of NPS found in the NPS samples collected by FEWS in 2013/14 contained 
controlled drugs (Home Office, 2014b). This is a similar level to the 19 per cent of samples 
that contained controlled drugs that were collected by FEWS in the first three months of 
operation in 2011 (Home Office, 2012b). However, the extent to which NPS contained 
controlled substances differed substantially depending on the source of the sample. A 
notable reduction was seen in the proportion of samples from the internet and headshops 
containing controlled drugs, though this was not the case with samples from festivals. In 
2013/14, of the substances found within NPS samples28, 3.0 per cent of substances from the 
internet and 4.3 per cent of substances from headshops were controlled NPS, compared with 
16.1 per cent and 63.5 per cent respectively in 2012/1329. However, 88.1 per cent of festival 
samples contained controlled drugs in 2013/14, a similar level to 2012/13 (83.8%) (Home 
Office, 2014b). To some extent, the market may now have stabilised since the research 
described in section 5.3 was undertaken, as FEWS data shows a reduction in the percentage 
of controlled NPS found in headshop and internet samples. 
Other test purchases have also shown variation in the substances supplied by internet sites. 
Davies et al. (2010) report that over six months of test purchases from internet-based legal 
high shops, there was variation in the content of 25 per cent of test purchases. Similarly, 
Baron et al. (2011) found that six out of seven products did not contain the advertised active 
ingredient.  
5.5.1 Mislabelling 
Retailers will often mislabel NPS with a disclaimer that they are ‘Not for human consumption’, 
and therefore provide no information about the use or harms of NPS, such as dosage or 
harm reduction advice (Newcombe, 2009:4; EMCDDA, 2011:5; Corazza et al., 2012). For 
example, a study of online NPS retailers found that 91.9 per cent (1,202) of products failed to 
list any side effects, 81.9 per cent (1,058) of products failed to list any contraindications30 and 
86.3 per cent (1,129) failed to list any warnings about potential interactions with other 
substances (Schmidt et al., 2011). This may potentially increase the harms of NPS, as 
uninformed users may take NPS in particularly dangerous ways. However, without full testing 
of a substance, any advice given may provide false assurances of safety for users.  
5.6 The development of novel NPS 
As previously described, there has been a rise in the number of novel NPS detected in 
Europe. It is plausible that there are many factors that are driving this rise, such as 
globalisation and rapid exchange of information on the internet. However, it has also been 
                                               
28 Many FEWS samples contain more than one substance, and as the data is presented in a way that does not link the 
substances found to the specific samples, it is only possible to describe the percentage of substances found that contain 
controlled drugs, as opposed to the percentage of samples that contain controlled drugs.  
29 FEWS collection plans vary on a year-to-year basis, and may target different aspects of the NPS market. Therefore each 
year’s figures are not directly comparable. 
30 A contraindication is a specific situation in which a drug should not be used because it may be harmful. 
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suggested that substance-by-substance controls may play a role in the generation of novel 
NPS (ACMD, 2012a. Dargan et al., 2011. Fattore and Fratta, 2011).  
Producers may quickly adapt to changes in legislation by marketing similar compounds that 
are not controlled. This phenomenon has occurred across different categories of NPS. For 
example, test purchases after the classification of synthetic cannabinoids revealed two 
compounds that were not covered by the UK’s generic legislation, and shortly after 
mephedrone was controlled, retailers marketed naphyrone as a replacement (Dargan et al., 
2011. Brandt et al., 2010). However, to an extent, this may be a more enduring problem for 
synthetic cannabinoids than other categories of NPS. As previously mentioned, 53 out of 56 
cathinones listed on the European Database of New Drugs are controlled in the UK. This is 
lower for synthetic cannabinoids, with 68 out of 111 being controlled. This reflects the 
success of the UK’s generic definitions in capturing the broad majority of cathinones, and the 
remaining challenge in covering the wider array of synthetic cannabinoids. 
Furthermore test purchases immediately after mephedrone control found that only one of the 
17 samples sold as naphyrone actually contained the substance. Most contained a mixture of 
banned cathinones, including mephedrone, suggesting that some retailers responded to 
classification by attempting to sell off their old stocks of recently controlled substances 
(Brandt et al., 2010). Retailers may also respond to control by offering ‘clearance sales’ on 
soon to be controlled NPS. At the time of writing, several internet sites were offering large 
discounts on alpha-Methyltryptamine (AMT), following an announcement that it would shortly 
be controlled as a Class A drug. 
5.7 Illicit supply 
Since classification, the remaining residual market for mephedrone has shifted to illicit 
suppliers, and there is evidence that the average price of mephedrone has increased. 
Reports from law enforcement agencies report an increase from around £10 per gram in 
2010 to around £20 per gram in 2012 (Davies and Murray, 2013). Other research also shows 
an increase in the price of mephedrone after classification (Winstock et al., 2010a). However, 
data from DrugScope suggests that the price has remained stable, at £19 a gram in 2010 
and 2012 (Davies and Murray, 2013). 
The illicit supply of NPS depends on whether there is considered to be sufficient demand for 
the substances and, therefore, only popular NPS are likely to move into criminal supply after 
formal control. So far, this only seems to be the case with mephedrone (EMCDDA, 2013b), 
and the majority of controlled NPS are not supplied by Organised Crime Groups (OCGs). 
However, as mephedrone is now a controlled drug, law enforcement agencies can disrupt 
illicit suppliers. There were 2,440 seizures of mephedrone by the police in England and 
Wales in 2011/12, totalling 83kg. Across the UK, the number of seizures increased by 16.4 
per cent, but the actual quantity seized fell by 20.0 per cent (Davies and Murray, 2013).  
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6. Motivations for NPS use 
Research into NPS suggests that reasons for initiating NPS use are broadly similar to 
reasons for initiating use of traditional illicit drugs, such as curiosity, boredom and peer 
pressure. When considering why people choose NPS over traditional illicit drugs, the most 
important reasons are likely to be market factors such as price, availability and perceived 
higher quality when compared to illicit drugs. The evidence that market factors are driving 
NPS use becomes particularly compelling when we consider that the majority of NPS users 
are also users of other illicit drugs. In the case of mephedrone it appears that it was 
considered to be better quality, cheaper, and more easily available than traditional illicit 
drugs, and thus there were strong reasons for users to switch from traditional club drugs.  
The evidence surrounding legality as a motivating factor is less clear. It appears that for 
existing illicit drug users it is not legality per se, but the factors that arise from this status such 
as quality, convenience and availability. However, for new users legality in itself may be a 
motivating factor. 
This chapter covers the reasons for the initiation and continuation of NPS use, what 
motivations there may be for choosing NPS over traditional illicit drugs, the subset of users 
who are motivated by a desire to avoid drug tests, and the inadvertent role the media plays in 
promoting NPS. 
6.1 Initiation and continuation of NPS use 
As well as being motivated by the psychoactive effects that NPS have, users have a range of 
other motivations for initiating drug use. Evidence in this area is by no means conclusive, as 
it is mainly from comments made in focus groups and interviews with small sample sizes. 
Nevertheless, it appears that the reasons for initiation of mephedrone use are curiosity and 
boredom (Newcombe, 2009). These reasons are similar to those given for initiation of 
traditional illicit substances among school-age children (Fuller, 2012). After initiation, reasons 
for continuance include liking the effect and developing a habit (Dargan et al., 2010).  
6.2 Motivations for choosing NPS over traditional illicit drugs 
As previously mentioned, most users of NPS are also users of traditional illicit drugs. 
However, a key feature of NPS over traditional illicit drugs is that most of them are legal when 
they first become available. This is demonstrated in the colloquial term ‘legal high’ that is 
sometimes used. The concern is that their legal status could be implying a level of safety and 
encouraging use over other illicit drugs. Evidence suggests a complex relationship between a 
substance’s legality and user preference. It appears that, for existing drug users, the legal 
status of NPS does not itself motivate use, nor does it imply that the substance is safe. 
However, there is limited evidence to suggest that, for those who do not use other drugs, the 
legal status may offer motivations for use, and may imply safety.  
Research with existing drug users has found that the legal status of mephedrone was not, in 
itself, driving its use. In a survey of 446 UK students, around half (52.9%) of respondents 
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reported that the legal status made no difference to their choices. Additionally, 74.2 per cent 
of respondents did not consider ‘legal highs’ to be safer than illicit drugs (Corazza et al., 2014).  
Similar results were also found in interviews with 23 adult mephedrone users: none of the 
respondents thought that legal highs were safe and the legal status of mephedrone did not 
affect their decision to use it (McElrath and O’Neill, 2010). This is supported by findings from 
a similar study (McElrath and Van Hout, 2011).  
Instead, a consistent theme is that the popularity of mephedrone was driven by factors 
relating to its legal status such as price, availability and purity. A study of 1,006 school, 
college and university students in the UK found that mephedrone was used for reasons 
including legality, accessibility, potency and price (Dargan et al., 2010). A survey of 1,506 
users of an online drug website found similar results (Carhart-Harris et al., 2011). Van Hout 
and Brennan (2011) interviewed 22 young mephedrone users and found that mephedrone 
initiation was based on several factors, such as exposure, widespread availability, curiosity, 
peer use, low quality of street drugs and competitive pricing.  
However, international evidence shows that the legal status of NPS can affect the 
perceptions of some users. In New Zealand, interviews with 58 BZP party pill users found 
that the legal status of BZP conferred several attributes (Sheridan and Butler, 2009). The 
legality suggested: it was safe, it was a guaranteed product, it had inferior effects to illicit 
drugs, users did not have to get involved with criminals, it was readily accessible, and that it 
was socially acceptable. The legal status of BZP was more of motivating factor in those that 
had not previously used illicit drugs than those that had.  
6.3 Drug tests 
One motivation for small subsets of NPS users is the inability of common drug tests to detect 
NPS use (Loeffler, 2012; UNODC, 2011:14; Ryall and Butler, 2011; Vandrey et al., 2012; 
Bird, 2010a/b). For those who have to undergo mandatory drug testing (armed forces 
personnel, transport workers, prisoners, criminals on probation, psychiatric patients etc.), 
NPS can offer a psychoactive experience without the negative implications of a positive drug 
test. Evidence in this area mainly comes from comments made in interviews and focus 
groups. This motivation may reduce over time, as some drug tests are now being updated to 
detect NPS. However, due to the rapidly moving NPS market, it is unlikely these tests will 
ever be able to cover all NPS. As mandatory drug testing is relatively uncommon in the UK it 
is likely that this factor is only driving a small amount of NPS use.  
6.4 Media reporting on NPS 
A further factor is that media reporting on NPS may have increased interest in NPS and 
possibly led to increased use (Dargan et al., 2010; Measham et al., 2010). Media reports 
often highlight the dangers of NPS, but also inadvertently advertise the potency, ready 
availability and legal status to potential users. As well as comments from users in focus 
groups and interviews, analysis of Google search trends has shown spikes in internet 
searches for NPS after prominent news media stories (Forsyth, 2012). However, these trends 
only show interest in NPS, and not actual purchases or use. 
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7. Harms of NPS use 
One of the main concerns surrounding NPS is the potential for these substances to cause 
harm. These could be short- or long-term harms to the user’s health, but also social harms 
such as increased acquisitive crime to fund addiction, anti-social behaviour, social isolation, 
unemployment and family breakdown. The available evidence suggests that the overall 
harms from NPS are low compared to the overall harms from traditional illicit drugs.  
7.1 Health harms of NPS use 
Evidence of NPS-related health harms is available from several national data sources: 
deaths related to NPS, NPS users in treatment, and poison centre contacts.  
The existing data is mostly focused on the acute short-term harms of use, but due to the 
relatively short time the majority of NPS have been in use less is known about chronic long-
term harms. There are also evidence gaps around acute toxicity which does not result in 
death. This is an area that should be closely monitored as there is a precedent in new drugs 
such as ketamine that initially appear to have relatively low harms, but are then later found to 
cause long-term harms to users’ health (ACMD, 2013).  
7.1.1 Deaths related to NPS use 
The National Statistics on drug related deaths show that overall deaths related to NPS use 
remain low compared to illicit drugs. In 2013, the ONS reported that there were 60 deaths 
related to NPS in England and Wales out of a total of 1,957 deaths from drug misuse overall 
(ONS, 2014a).  
However, deaths related to NPS have been increasing. There were 60 NPS related deaths in 
2013, a relatively small increase from 52 deaths in 2012, but a sharp increase from 29 deaths 
in 2011, following a period of relative stability (see figure 4). The increases in NPS related 
deaths have largely been driven by an increase in deaths related to cathinones (6 in 2011, 18 
in 2012, and 26 in 2013) alongside deaths related to other NPS31 that are not individually 
reported by the ONS. Whereas GHB/GBL-related deaths have remained relatively stable, 
with year-to-year variation (20 in 2011, to 13 in 2012, 18 in 2013). 
                                               
31 The ONS include 29 different substances in their measure of NPS-related deaths. This includes NPS such as 
synthetic cannabinoids, 6-APB, methoxetamine, methiopropamine and alpha-methyltryptamine. 
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Figure 4: Drug-related deaths where selected substances are mentioned on death 
certificates, ONS, 2007 to 2013 
 
Another source of data on drug-related deaths is the National Programme on Substance 
Abuse Deaths (np-SAD). np-SAD gives us additional insight into NPS-related deaths, as they 
publish more breakdowns on the specific substances involved than those provided by the 
ONS. 
In total, np-SAD report that there were 68 deaths involving NPS in 2012, an increase from 51 
in 2011 and 42 in 2010, and a sharp rise from 10 in 2009 (Figure 5).  
Figure 5: NPS-related deaths reported by coroners, np-SAD, 2009 to 2012 
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There are several key differences between ONS and np-SAD statistics (see Table 7) and 
these affect the overall figures that are produced. The effects these differences have are 
discussed below. 
Table 7: Differences between ONS and np-SAD statistics on drug-related deaths 
 ONS np-SAD 
Coverage: England and Wales (separate 
official statistics are produced for 
Scotland and Northern Ireland) 
UK 
Mandatory 
reporting? 
Coroners are legally required to 
register deaths 
Participation by Coroners is 
voluntary 
Deaths 
recorded by: 
Year registered Year of death 
Non-NPS 
included? 
Yes, only khat Yes, several natural products 
including khat and mescaline, PMA, 
PMMA, two dietary supplements 
and five types of anabolic steroids 
 
Within the np-SAD data, cathinones in general and specifically mephedrone have the 
greatest number of mentions. In 2012, mephedrone was listed as the cause of 14 deaths. 
Within the NPS category in 2012, only PMA caused more deaths (17). However, PMA is not 
an NPS, and it is likely that these deaths are related to adulterated ecstasy32. The inclusion of 
these substances (specifically PMA) is one of the reasons that the np-SAD total is higher 
than the ONS total. 
There are often delays in the registration of deaths and this can make year-to-year 
comparisons less meaningful. The ONS record deaths to the year they were registered in 
rather than the year they occurred. This is less of a problem for deaths not related to drug use 
as only 4.5 per cent of all deaths registered in 2012 occurred in a previous year (ONS, 2014b).  
However, drug-related deaths are often more complex, with around four in ten involving 
multiple substances, and a third involving alcohol. This leads to longer coronial inquiries, and 
consequently just over half (1,488 out of 2,955) of the deaths related to drug poisoning33 
registered in 2013 occurred in years prior to 2013 (ONS, 2014a). 
Unlike the ONS, np-SAD report deaths in the year they occurred, but this does lead to the 
figures being revised once they have been published. The effect these two different methods 
have can be seen in a comparison of cathinone deaths: the np-SAD figures show a peak in 
2010, whereas the ONS figures show that cathinone deaths are continuing to rise (Figure 6).  
                                               
32 PMA and PMMA can be found in ecstasy pills. It is likely that those who died were intending to take MDMA.  
33 Drug-poisoning deaths is a wider measure than the drug-misuse deaths, thatincludes accidental deaths not related to 
drug misuse and suicides. 
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Figure 6: Deaths related to cathinones, ONS and np-SAD, 2009 to 2013 
 
7.1.2 Treatment data 
National Statistics from Public Health England show that treatment demand for mephedrone 
and GHB/GBL use is low compared to many other traditional illicit drugs, but has increased 
over recent years.  
The number of over-18s entering treatment who report mephedrone use has increased since 
2010/1134 (see figure 7). In 2010/11, 839 clients entered treatment reporting mephedrone 
use; this rose to 1,630 clients in 2012/13 (PHE, 2013). A similar picture can also be seen in 
under-18s. In 2010/11, 972 under-18s entered treatment reporting mephedrone use; this then 
increased to 1,788 in 2012/13. The figures presented above include all clients who entered 
treatment reporting mephedrone use, and these clients may have other drugs as their 
primary drug of misuse.  
                                               
34 A code for mephedrone was only added to the National Drug Treatment Monitoring System Core Data Set in 2010/11. Any 
clients reporting mephedrone prior to this were counted in the total measure, but separate figures could not be produced. 
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Figure 7: New treatment entrants who reported mephedrone use, England, PHE, 
2010/11 to 2012/13 
 
Unlike treatment entrants for drugs such as heroin and crack cocaine, mephedrone users are 
generally young. The National Treatment Agency for Substance Misuse (NTA) found that, in 
2012, 56 per cent of over-18s in treatment for mephedrone were between 18 and 24 years 
old (NTA, 2012). 
Treatment for GHB/GBL use is low compared to both mephedrone and traditional illicit drugs, 
but as with mephedrone it has been increasing. The number of over-18s entering treatment 
who report GHB/GBL use has increased from 135 in 2010/11 to 231 in 2012/13. 
A report on club drugs35 (including NPS) by the NTA36 found that users in treatment for these 
drugs had positive prospects. Six out of ten (61%) treatment exits involving over-18 club drug 
users were successful. In 2012/14, club drug users comprised a small proportion of all those 
in treatment, five per cent of over-18s and fifteen per cent of under-18s (PHE, 2013). The 
NTA concluded that club drugs were unlikely to replace heroin and crack as the primary 
drivers of demand for treatment (NTA, 2012).  
The increase in treatment for mephedrone is likely to reflect a genuine increase in those 
experiencing problems with mephedrone use, but could also be partially attributable to 
increased awareness and capability of treatment services. Also, current treatment data cannot 
give an indication of the scale of future provision, the unknown untreated population, and there 
are also unknowns surrounding the addictive potential of some NPS. For the minority who 
develop problems with NPS use, there is likely to be a time lag, between first use of NPS, and 
then developing problematic use or dependency, and then presenting to treatment services.  
                                               
35 The NTA include ecstasy, ketamine and methamphetamine in this category, alongside mephedrone and GHB/GBL. 
36 Now part of Public Health England. 
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7.1.3 Poison centre contacts 
The UK’s National Poison Information Service (NPIS) provides information and advice to 
health professionals through telephone enquiries and online access to its TOXBASE service. 
Figures from these services are not a direct measure of patient presentations or toxicity, as 
advice is more likely to be sought for sicker patients or when unfamiliar substances are 
involved. Additionally, the data relies on users and healthcare professionals providing 
accurate information on the substances, as toxicological confirmation is not usually available. 
Despite this, they do, however, give a good indication of the substances being encountered 
by NHS physicians, and therefore provide an indication of non-fatal intoxications from NPS. 
Between 2011/12 and 2012/13, there were increases in the numbers of telephone enquiries 
(49%) and TOXBASE accesses (128%) relating to uncontrolled NPS. Mephedrone remains 
the most frequently mentioned substance.  
 There were 8,432 TOXBASE enquiries regarding mephedrone in 2012/13, up 36.1 per 
cent from 2011/12, but down from a peak in March 2010.  
 For BZP there were 1,574 enquiries in 2012/13, down 5.0 per cent from 2011/1237.  
 For GHB there were 1,476 enquiries in 2012/13, down 13.7 per cent from 2011/1237.  
‘Legal highs’ (not otherwise specified) and mephedrone were in the top ten for telephone 
enquiries. Other NPS asked about included alpha-Methyltryptamine (13th), synthetic 
cannabinoids (15th), 5/6-APB (16th) and 25I-NBOMe (22nd).  
Figure 8 shows monthly trend data for TOXBASE accesses for several different NPS. There 
was a peak in cathinones around February/March 2010; this is predominantly mephedrone 
but there are also a smaller amount of accesses related to methcathinone. After peaking in 
March 2010, mephedrone accesses have reduced but remain high relative to other NPS. 
This reflects the enduring popularity of mephedrone since it was controlled in April 2010 and 
the relative obscurity of other NPS. Immediately after mephedrone was classified there was 
an increase in access related to naphyrone. This drug was marketed as a legal replacement 
for mephedrone. Accesses related to naphyrone decreased following its classification in July 
2010.  
                                               
37 These declines could be down to increasing clinical familiarity with these substances rather than declining use.  
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Figure 8: Monthly TOXBASE accesses relating to selected drugs of abuse, NPIS, 
March 2009 to March 2013 
  
Analysis of poison centre contacts suggests there is a correlation between legislation 
controlling specific NPS and a reduction in poison centre contacts (Loeffler and Craig, 2013). 
A similar pattern is also visible in presentations to an emergency department (Wood et al., 
2012d). 
7.2 Social harms of NPS use 
Data on the social harms caused by NPS are extremely limited. However, there is no 
evidence to suggest that NPS are driving crime and other social harms to the same degree 
as heroin and crack cocaine.  
It is plausible to expect that societal harms have the potential to be comparable to those of 
the drugs NPS imitate (ACMD, 2009). At present NPS are not imitating drugs that are the 
main drivers of crime and other social harms (heroin and crack cocaine). Instead they appear 
to be imitating, displacing and supplementing drugs such as ecstasy, amphetamine, cocaine, 
cannabis and ketamine. However, opioid NPS such as AH-7921 and MT-45 have now been 
identified, and despite the limited evidence of use, these NPS could potentially become 
drivers of crime and other social harms. 
There are, however, limited reports that some problematic mephedrone users are involved in 
violent behaviour, though these tend to be based on users who are already involved with 
services and often users of other drugs. As such they are unlikely to represent the vast 
majority of mephedrone users.  
There have been reports from drug treatment workers that suggest heroin users who start 
injecting mephedrone are more difficult to deal with (Daly, 2012). Similarly, a study of 67 
mephedrone users in contact with services identified a ‘violent subset’, though these tended 
to report daily mephedrone use alongside other drugs and alcohol (Brookman, 2014). 
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8. Conclusion 
This report has provided an overview of the available evidence on NPS. This is a relatively 
new and developing area of study; many innovative methodologies are being used and 
conventions surrounding how best to research NPS are still being established. 
NPS is a dynamic and fluid area. High-quality research takes time to produce and these long 
timescales are not best suited to providing the most up-to-date evidence in a fast-moving 
market. For example, there are many articles about mephedrone prior to and immediately 
after classification, but a relative dearth of articles since then. While high-quality research into 
NPS is very beneficial, there are issues surrounding timeliness that need considering.  
Fundamentally, NPS is a difficult area to research; new NPS are appearing on the market at 
an increasing rate and they are marketed and packaged in ways that decrease the validity of 
commonly used self-reporting methods. Additionally, only a small proportion of NPS identified 
achieve even limited popularity. Given these issues, it would be unwise to comprehensively 
research all NPS identified. Instead, resources would be better focused on the most popular 
NPS, groups of NPS, or NPS as a whole.  
As discussed in the introduction and throughout this review, there are issues with how the 
concept of NPS is defined. This is important when estimating the overall extent of the NPS 
phenomenon, as the inclusion or exclusion of different substances as NPS can considerably 
affect overall estimates of scale. It is often the case that many of the larger estimates of NPS 
activity have the loosest or most expansive definition of what an NPS is.  
8.1 Summary of the evidence 
Throughout the review it has become clear that some areas of research on NPS are better 
developed and understood than others.  
There is good evidence on the incidence of NPS, with well-established systems effectively 
identifying new NPS as they emerge on the UK and European markets. These systems show 
us that the rate at which NPS are appearing on the European and international market is 
increasing. The picture in the UK is slightly different, with greater year-to-year variation. 
There is relatively detailed information available about the use of some NPS (such as 
mephedrone) but less is known about less commonly used NPS or the overall scale of NPS 
use. Data on the prevalence of NPS use (for example, the CSEW) shows that mephedrone is 
more popular than other types of NPS measured, but its use has been declining. Smaller-
scale studies in subgroups have identified interesting results, although these findings need 
considering within the limitations of the method employed. 
When used together the several sources of data on health harms provide a reasonable yet 
incomplete picture of some of the current health problems with NPS use. These sources 
show that the health harms from NPS have been increasing but remain low compared to 
some traditional illicit drugs. However, there is additional scope for improvement in this area 
and there are large evidence gaps around long-term health harms.  
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8.2 Evidence gaps 
This review has identified a number of gaps in the evidence base on NPS. The report of the 
expert panel has also identified many of these gaps, and contains recommendations for 
improving our knowledge in these areas. Many of these gaps are not unique to NPS, as the 
evidence base on traditional illicit drugs is also underdeveloped in a number of areas. As 
there is considerable interplay between traditional illicit drugs and NPS, many of these gaps 
may be best filled by research that aims to improve our understanding of drug use in general, 
rather than research aimed specifically at NPS. It is also possible that some of these gaps 
may be filled by ongoing cross-government and wider academic research into NPS. 
 Given the large number of NPS detected, and the fluidity of the NPS market, there is an 
evidence gap surrounding the prevalence of NPS use. It is possible that some NPS 
are only used for a short amount of time, but it is not possible to gauge the extent to 
which this happens as the current population level prevalence indicators are unsuited 
for detecting this.  
 Similarly, we do not currently have a general population measure of the total level of 
NPS use, although the 2014/15 CSEW includes questions aimed at improving 
measurement at population level. 
 Given the discrepancy between the way NPS are labelled and the substances they 
contain, there are limitations with the reliability and validity of prevalence data. Many 
users will not know the exact substances they are taking, and therefore self-report 
surveys only provide a measure of the substances users intended to take, rather than 
the actual substance consumed.  
 Less is known about the use of NPS among subgroups other than night-time 
economy participants. Of all the subgroups researched, participants in the night-time 
economy have the greatest amount of research, although this is still limited. It is 
possible that NPS may be used in subgroups other than those mentioned in this report, 
but a lack of research makes it difficult to identify these subgroups, the NPS they use, 
and to quantify their use of NPS.  
 There is a lack of evidence on the long-term health harms of NPS use. It is not 
currently possible to know the long-term harm of some NPS, as they have not been in 
use for a long time. However, this is an area that needs monitoring, as there is a 
precedent for emerging drugs (ketamine) to cause chronic harms. 
 There is also a lack of evidence on the acute health harms of NPS use. The only 
indication of acute non-fatal intoxications is the NPIS, although there are several 
caveats that limit the insight that can be gained. Data on acute intoxications (for 
example, A&E presentations and hospital admissions) for NPS use would complement 
the existing sources; however, the ICD-10 system used to code hospital admissions 
does not include codes for NPS (nor a variety of traditional illicit drugs), which makes it 
difficult to systematically collect this data (Wood et al., 2014).  
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 The extent to which NPS use drives social harms is unknown. We are currently 
reliant on making assumptions based on existing knowledge of illicit drugs that are 
similar to NPS. 
 Despite legislation being one of the primary means used to tackle NPS and illicit drug 
use, there is an evidence gap on the impact and effectiveness of legislation, and we 
cannot conclusively state that falls in mephedrone use are exclusively due to control. 
This is a problematic area to research as it is not possible to establish a counterfactual, 
or to isolate the impact of the other factors that may have led to falls in drug use.  
 Much of the research covered in this review has focused on mephedrone and less is 
known about other types of NPS. We do not know the extent to which mephedrone 
users are similar or dissimilar to other NPS users and therefore generalising results 
from mephedrone studies to wider NPS is problematic. Mephedrone is now controlled, 
and therefore the findings may not apply to currently uncontrolled NPS.  
 This report has identified evidence that suggests NPS both displace and supplement 
conventional illicit drugs. However, the exact factors and mechanisms that affect 
displacement and supplementation are unclear.  
 The research identified on purchasing habits suggests that only a small amount of users 
purchase NPS online. However, the extent to which individuals within social groups 
purchase online and then distribute within their social group is unknown.  
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